摘要
目的:分析脂氧素A4(LXA4)在前列腺癌(PC)患者血清中的表达情况及临床意义。方法:选取2016年9月—2019年9月遵义医学院附属医院泌尿外科收治的PC患者60例为PC组;选取同期收治的前列腺增生患者48例为前列腺增生组;选取同期体检健康人员50例为健康组。采用双抗体夹心酶联免疫吸附测定法检测三组血清中LXA4的表达水平。观察三组血清LXA4水平变化,分析血清LXA4对PC的诊断价值,比较不同TNM分期PC组患者血清LXA4水平。结果:PC组LXA4水平低于前列腺增生组和健康组,差异有统计学意义(P=0.000);血清LXA4对PC具有较高的诊断价值(P<0.001),其AUC=1.00(95%CI:0.976~1.000);PC组患者血清LXA4水平随TNM分期的升高而降低,差异有统计学意义(P=0.000)。结论:LXA4与PC的形成、进展存在相关性,对于肿瘤的生长可能起到关键性的抑制作用。
Objective:To analyze the expression and clinical significance of lipoxin A4(LXA4)in serum of patients with prostate cancer(PC).Methods:Sixty patients with PC admitted to the Department of Urology of the Affiliated Hospital of Zunyi Medical University from September 2016 to September 2019 were selected as the PC group.Forty-eight patients with prostatic hyperplasia treated in the same period were selected as prostatic hyperplasia group.A total of fifty healthy persons in the same period were selected as the healthy group.The expression level of LXA4 in serum of the three groups was detected by double antibody sandwich ELISA.The changes of serum LXA4 level in the three groups were observed,the diagnostic value of serum LXA4 for PC was analyzed,and the serum LXA4 level in PC groups with different TNM stages were compared.Results:The LXA4 level of the PC group was lower than that of the prostatic hyperplasia group and the healthy group,and the difference was statistically significant(P=0.000).Serum LXA4 had high diagnostic value for PC(P<0.001),and its AUC was 1.00(95%CI:0.976-1.000).The serum LXA4 level in PC group was decreased with the increase of TNM stage,the difference was statistically significant(P=0.000).Conclusion:LXA4 is correlated with the formation and progression of PC,which may play a key inhibitory role in tumor growth.
作者
崔伟
朱明兰
陈书练
李晓光
罗旭
Cui Wei;Zhu Ming-lan;Chen Shu-lian;Li Xiao-guang;Luo Xu(Department of Urology,the Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou Province,China;Department of Aesthetic Surgery,the Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou Province,China)
出处
《中外医药研究》
2022年第18期117-119,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
基金
贵州省卫生计生委科学技术基金项目(编号:gzwjkj2017-1-006)。